@misc{oai:repo.qst.go.jp:00069862,
 author = {Furukawa, Takako and Saito, Yuriko and Hasegawa, Sumitaka and Saga, Tsuneo and Fujibayashi, Yasuhisa and 古川 高子 and 齋藤 有里子 and 長谷川 純崇 and 佐賀 恒夫},
 month = {Sep},
 note = {Zinc-63 is a positron emitter with half life of 30 min. It can be produced using a small clinical cyclotron targeting Cu-63, the most abundant Cu isotope in nature, which makes Zn-63 a potentially attractive radionuclide for clinical imaging. Zinc, one of the essential trace elements, is contained in many enzymes and functional proteins such as transcription factors as a critical component. The usefulness of radiolabeled Zn-EDDA in imaging of pancreatic function was reported earlier: the uptake of Zn-EDDA into pancreas was shown to reflect the active production of Zn-containing enzymes. As Zn is essential for cell proliferation, it would be reasonable to expect that rapidly growing tissues, such as cancer, need larger amount of Zn than the others. Accordingly, we were prompted to explore the possibility to use radiolabeled Zn-EDDA for cancer imaging. We examined cellular uptake of Zn-65 labeled Zn-EDDA, Zn content, and expression of Zn transporters, comparing several cancer cell lines, together with the biodistribution of Zn-65 labeled Zn-EDDA in tumor-bearing mice. The cellular uptake was found to be correlated with Zn content, but not with the expression of any particular transporter tested, suggesting that the uptake reflects the physiological needs of the cells. The accumulation of Zn-65 in the tumor xenografts ranged 2.3-4.2 %ID/g, tumor/blood ratio 3.5-8.1, and tumor/muscle ratio 5.5-12. Bone, liver, kidney and upper intestine, other than pancreas, accumulated high (5< %ID/g) amount of the radioactivity. Zn-EDDA would have potential as a cancer imaging agent, though the use would be restricted in limited tissues., World Molecular Imaging　Congress},
 title = {Basic Evaluation of Zn-EDDA for Cancer Imaging},
 year = {2009}
}